Impact of the use of botulinium toxin type A in the current treatment off chronic migraine in adults
International Journal of Neurology · 30.12.2023 · 57 · 54
DOI: 10.62486/ijn202354 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Neurology, online erschienen am 30.12.2023. Verfasst von Tiago Goulart Appel und 1 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Migraine is a complex neurological disorder that causes recurrent, localized headaches and is associated with hyperstimulation of the muscles in the frontal, temporal, occipital, and trapezius regions. Botulinum toxin acts on the motor plate by blocking the action of acetylcholine, thereby producing an analgesic effect in these patients. Materials and methods: A systematic review will be conducted using the PubMed and Scielo electronic databases. The search criteria were studies and reviews published between 2014 and April 2020 to identify transitional research focused on the use of botulinum toxin in patients with chronic migraine.
Results
Nine articles that met the criteria for evaluating the efficacy of chronic migraine treatment using Onabotulimumtoxin A were included. An average of three cycles of the PREEMPT treatment protocol were performed. The mean age was 47 years, and 82.5% were women. The frequency of headache days/month and its intensity were significantly reduced by 30 to 50%, and this improvement was maintained over time.
Conclusion
Randomized studies have shown that long-term, fixed-dose, fixed-site intramuscular injection therapy with botulinum toxin A is a safe and effective procedure with insignificant complications in appropriately selected patients.
Zitieren
APA
Appel, T. G., & Neto, J. F. D. O. (2023). Impact of the use of botulinium toxin type A in the current treatment off chronic migraine in adults. International Journal of Neurology, 57, 54. https://doi.org/10.62486/ijn202354
Vancouver
Appel TG, Neto JFDO. Impact of the use of botulinium toxin type A in the current treatment off chronic migraine in adults. International Journal of Neurology. 2023;57:54. doi:10.62486/ijn202354
BibTeX
@article{Appel2023,
author = {Appel, Tiago Goulart and Neto, João Francisco De Oliveira},
title = {Impact of the use of botulinium toxin type A in the current treatment off chronic migraine in adults},
journal = {International Journal of Neurology},
year = {2023},
volume = {57},
pages = {54},
doi = {10.62486/ijn202354}
}
EUVIMED